Skip to main content
S&P 5007,818.93+0.58%DOW51,521.28+0.49%NASDAQ27,599.89+0.45%BTC$85,552.00-0.29%ETH$2,697.47-0.58%GOLD$4,187.80+0.02%OIL$90.23+0.88%
Smart Investors Daily
SID Premium
RV

NASDAQ · RVPH

Reviva Pharmaceuticals Holdings, Inc.

Healthcare · Biotechnology

$0.35

Up+$0.00 (+0.20%)

Updated Oct 6, 2026, 11:11 PM

SID Score

3.6/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
46.49M
P/E ratio
-1.25
Dividend yield
0.00%
52-week range
$0.26 – $23.20
Volume
13.18M
Avg. volume
10.35M

Price performance · RVPH

RVPH price history

1M range · 0 trading sessions · Daily adjusted prices

RVPH does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest RVPH news

The latest Smart Investors Daily articles mentioning RVPH.

Stock researchCompany · Overview

RVPH research

Overview

Company profile and research snapshot.

Company profile

Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$5.87
Implied upside
—
Analysts
13
RVPH recent ratings
DateFirmRatingTarget
Apr 8, 2026Maxim GroupHold—
Mar 5, 2026D. Boral CapitalHold—
Jan 5, 2026Chardan CapitalBuy—
Dec 23, 2025HC Wainwright & Co.Buy—
Dec 23, 2025D. Boral CapitalBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 22, 2026

Reviva to Participate in the Lytham Partners Fall 2026 Investor Conference

The Company invites individual and institutional investors, as well as advisors and analysts with an interest in the life sciences sector, to attend the corporate presentation at https://lythampartners.com/fall2026/ CUPERTINO, Calif., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (OTCQB: RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), infla

Benzinga · Aug 12, 2026

Reviva Pharmaceuticals Q2 EPS $(0.19) Beats $(0.39) Estimate

Reviva Pharmaceuticals (NASDAQ:RVPH) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.39) by 50 percent. This is a 92.08 percent increase over losses of $(2.40) per share

Yahoo · Jun 26, 2026

Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand Viewing

NEW YORK, June 26, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the June 24th & 25th Life Sciences Virtual Investor Forum are now available for on-demand viewing. REGISTER AND VIEW PRESENTATIONS HERE Select companies are accepting 1x1 management meeting requests through June 19th. Please Schedule 1x1 Meetings here. The presentations will be available 24/7 for 90 days. Investors, advisors, and ana

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By